Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17174058,flow-rate,"The analysis was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with gradient elution at a flow-rate of 0.35 ml/min.",Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174058/),[ml] / [min],0.35,1393,DB00393,Nimodipine
,11986913,C-max,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],10.208,3661,DB00393,Nimodipine
,11986913,t-max,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,1,3662,DB00393,Nimodipine
,11986913,minimum concentration,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],1.2929,3663,DB00393,Nimodipine
,11986913,half-life,"At steady-state regular nimodipine reached a C-max of 10.208 +/- 0.317 ng/ml, at a t-max of 1 h; minimum concentration 6 h after dosage was 1.2929 +/- 0.411 ng/ml, half-life was estimated in 2.9 h.",Comparison of two nimodipine formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,2.9,3664,DB00393,Nimodipine
,11986913,C-max,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],11.885,3665,DB00393,Nimodipine
,11986913,t-max,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,1,3666,DB00393,Nimodipine
,11986913,minimum concentration,Meanwhile nimodipine AP 120 mg reach a C-max of 11.885 +/- 0.403 ng/ml; a t-max of 1 h with a minimum concentration 24 h after the last dose of 4.2387 +/- 0.353 ng/ml (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [ml],4.2387,3667,DB00393,Nimodipine
,11986913,Apparent half-life,Apparent half-life was calculated in 17.8 h (P < 0.001).,Comparison of two nimodipine formulations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),h,17.8,3668,DB00393,Nimodipine
,11986913,Area under the curve,"Area under the curve for the 24 h period was 143.76 ng/ml/min for regular nimodipine and 183.7 ng/ml/min for nimodipine AP 120 mg (P < 0.001), indicating better bioavailability.",Comparison of two nimodipine formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [min·ml],143.76,3669,DB00393,Nimodipine
,11986913,Area under the curve,"Area under the curve for the 24 h period was 143.76 ng/ml/min for regular nimodipine and 183.7 ng/ml/min for nimodipine AP 120 mg (P < 0.001), indicating better bioavailability.",Comparison of two nimodipine formulations in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11986913/),[ng] / [min·ml],183.7,3670,DB00393,Nimodipine
up to,15081140,maximum solubility,"The optimal microemulsion formulation consisted of 8% Labrafil M 1944CS, 30% Cremophor RH 40/ethanol (3:1) and water, with a maximum solubility of NM up to 6.4 mg/ml, droplet size of 30.3 +/- 5.3 nm, and no ciliotoxicity.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),[mg] / [ml],6.4,10186,DB00393,Nimodipine
,15081140,absolute bioavailability,"After a single intranasal administration of this preparation at a dose of 2 mg/kg, the plasma concentration peaked at 1 h and the absolute bioavailability was about 32%.",Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15081140/),%,32,10187,DB00393,Nimodipine
,24374219,relative bioavailability,"In comparison with the commercial reference tables, the relative bioavailability of the two formulations was 67.0% and 121.1%, respectively, indicating the solid dispersion technique was more efficient than the micronization technique in terms of solubilization capability and absorption enhancement.",A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374219/),%,67.0,13464,DB00393,Nimodipine
,24374219,relative bioavailability,"In comparison with the commercial reference tables, the relative bioavailability of the two formulations was 67.0% and 121.1%, respectively, indicating the solid dispersion technique was more efficient than the micronization technique in terms of solubilization capability and absorption enhancement.",A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24374219/),%,121.1,13465,DB00393,Nimodipine
,15066224,Oral systemic bioavailability,"Oral systemic bioavailability of NM in rats was 1.17 %, nasal dosing improved bioavailibility to 67.4 %.",Distribution of nimodipine in brain following intranasal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15066224/),%,1.17,18870,DB00393,Nimodipine
,15066224,bioavailibility,"Oral systemic bioavailability of NM in rats was 1.17 %, nasal dosing improved bioavailibility to 67.4 %.",Distribution of nimodipine in brain following intranasal administration in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15066224/),%,67.4,18871,DB00393,Nimodipine
>,23018841,extraction recovery,The lower limit of quantification was 0.312 ng/mL and the extraction recovery was >90.4% for limonin.,Determination of limonin in dog plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018841/),%,90.4,18877,DB00393,Nimodipine
,30613141,relative bioavailability,"Remarkable improvements in Cmax and AUC0-∞ from NMP-NLC were obtained from pharmacokinetic experiments, and the relative bioavailability of NMP-loaded nanostructured lipid systems was 160.96% relative to NMP suspensions.",Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30613141/),%,160.96,19099,DB00393,Nimodipine
,7757317,"normalized AUCss,norm","The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·kg,11.6,22863,DB00393,Nimodipine
,7757317,"normalized AUCss,norm","The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·kg,12.3,22864,DB00393,Nimodipine
,7757317,AUC-ratio,"The normalized AUCss,norm were 11.6 (5.0) kg x h x 1(-1) at glibenclamide monotherapy and 12.3 (5.1) kg x h x 1(-1) after combined medication, resulting in an AUC-ratio for glibenclamide of 109 (23%).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),,109,22865,DB00393,Nimodipine
,7757317,elimination half-lives,Mean elimination half-lives were determined as 2.7 (0.9) h after glibenclamide alone and 3.6 (1.9) h after nimodipine comedication.,The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h,2.7,22866,DB00393,Nimodipine
,7757317,elimination half-lives,Mean elimination half-lives were determined as 2.7 (0.9) h after glibenclamide alone and 3.6 (1.9) h after nimodipine comedication.,The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h,3.6,22867,DB00393,Nimodipine
,7757317,Cmax,"There was no evidence of significant alterations in glibenclamide efficiency as seen from glucose and insulin kinetics after the simultaneous administration of glibenclamide and nimodipine (insulin Cmax, 57.0 (30.8) mU/l after glibenclamide and 64.4 (32.1) mU/l after combined treatment).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),[mu] / [l],57.0,22868,DB00393,Nimodipine
,7757317,Cmax,"There was no evidence of significant alterations in glibenclamide efficiency as seen from glucose and insulin kinetics after the simultaneous administration of glibenclamide and nimodipine (insulin Cmax, 57.0 (30.8) mU/l after glibenclamide and 64.4 (32.1) mU/l after combined treatment).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),[mu] / [l],64.4,22869,DB00393,Nimodipine
,7757317,AUCss,"Nimodipine pharmacokinetics under nimodipine and glibenclamide steady-state conditions were similar to findings in literature: AUCss,norm 0.10 (0.04) microgram x h x 1(-1), Css,max 20.7 (8.3) microgram x 1(-1).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),h·μg,0.10,22870,DB00393,Nimodipine
,7757317,"Css,max","Nimodipine pharmacokinetics under nimodipine and glibenclamide steady-state conditions were similar to findings in literature: AUCss,norm 0.10 (0.04) microgram x h x 1(-1), Css,max 20.7 (8.3) microgram x 1(-1).",The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757317/),μg,20.7,22871,DB00393,Nimodipine
,27042060,polydispersity index,"Using Solutol(®) HS15, the NIM-loaded self-assembled nanomicelles displayed a near-spherical morphology with a narrow size distribution of 12.57 ± 0.21 nm (polydispersity index =0.071 ± 0.011).",One-step self-assembled nanomicelles for improving the oral bioavailability of nimodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042060/),,0.071,23897,DB00393,Nimodipine
,3588513,Emax,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,100,24274,DB00393,Nimodipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,10,24275,DB00393,Nimodipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,65,24276,DB00393,Nimodipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,68,24277,DB00393,Nimodipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,78,24278,DB00393,Nimodipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,21,24279,DB00393,Nimodipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,136,24280,DB00393,Nimodipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,33,24281,DB00393,Nimodipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,56,24282,DB00393,Nimodipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,6,24283,DB00393,Nimodipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,81,24284,DB00393,Nimodipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,56,24285,DB00393,Nimodipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,16,24286,DB00393,Nimodipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,29,24287,DB00393,Nimodipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],290,24288,DB00393,Nimodipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],61,24289,DB00393,Nimodipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],177,24290,DB00393,Nimodipine
,2662635,oral bioavailability,"Nimodipine has low oral bioavailability (2.7-27.9 percent), a short half-life (2 h), is highly protein bound (98-99 percent), and is hepatically metabolized.",Nimodipine in the treatment of subarachnoid hemorrhage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2662635/),%,2.7-27.9,32794,DB00393,Nimodipine
,2662635,half-life,"Nimodipine has low oral bioavailability (2.7-27.9 percent), a short half-life (2 h), is highly protein bound (98-99 percent), and is hepatically metabolized.",Nimodipine in the treatment of subarachnoid hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2662635/),h,2,32795,DB00393,Nimodipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,77.56,36212,DB00393,Nimodipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,84.23,36213,DB00393,Nimodipine
,12583003,extraction efficiency,"The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively.",A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),%,83.94,36214,DB00393,Nimodipine
,12583003,half-life (t(1/2),The results inferred that NC is rapidly absorbed in rabbits and has a short half-life (t(1/2) = 1.34 h).,A simple method for nicardipine hydrochloride quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12583003/),h,1.34,36215,DB00393,Nimodipine
,8832305,Cmax,"Under steady-state conditions the elderly reached significantly higher Cmax (g.mean/SD: 23.3/1.62 micrograms/l) and AUC-values (47.5/1.62 micrograms*h/l) than the young volunteers (13.5/2.03 micrograms/l, and 25.7/1.73 micrograms*h/l, respectively).",The influence of age on the pharmacokinetics of nimodipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),[μg] / [l],23.3,37981,DB00393,Nimodipine
,8832305,AUC-,"Under steady-state conditions the elderly reached significantly higher Cmax (g.mean/SD: 23.3/1.62 micrograms/l) and AUC-values (47.5/1.62 micrograms*h/l) than the young volunteers (13.5/2.03 micrograms/l, and 25.7/1.73 micrograms*h/l, respectively).",The influence of age on the pharmacokinetics of nimodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),[h·μg] / [l],47.5,37982,DB00393,Nimodipine
,8832305,AUC-,"Under steady-state conditions the elderly reached significantly higher Cmax (g.mean/SD: 23.3/1.62 micrograms/l) and AUC-values (47.5/1.62 micrograms*h/l) than the young volunteers (13.5/2.03 micrograms/l, and 25.7/1.73 micrograms*h/l, respectively).",The influence of age on the pharmacokinetics of nimodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),[h·μg] / [l],1.62,37983,DB00393,Nimodipine
,8832305,AUC-,"Under steady-state conditions the elderly reached significantly higher Cmax (g.mean/SD: 23.3/1.62 micrograms/l) and AUC-values (47.5/1.62 micrograms*h/l) than the young volunteers (13.5/2.03 micrograms/l, and 25.7/1.73 micrograms*h/l, respectively).",The influence of age on the pharmacokinetics of nimodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),[μg] / [l],13.5,37984,DB00393,Nimodipine
,8832305,AUC-,"Under steady-state conditions the elderly reached significantly higher Cmax (g.mean/SD: 23.3/1.62 micrograms/l) and AUC-values (47.5/1.62 micrograms*h/l) than the young volunteers (13.5/2.03 micrograms/l, and 25.7/1.73 micrograms*h/l, respectively).",The influence of age on the pharmacokinetics of nimodipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),[h·μg] / [l],25.7,37985,DB00393,Nimodipine
,8832305,absolute bioavailability,The absolute bioavailability was 10.6/1.60% in the elderly and 5.4/2.11% in young subjects.,The influence of age on the pharmacokinetics of nimodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),%,10.6,37986,DB00393,Nimodipine
,8832305,absolute bioavailability,The absolute bioavailability was 10.6/1.60% in the elderly and 5.4/2.11% in young subjects.,The influence of age on the pharmacokinetics of nimodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832305/),%,5.4,37987,DB00393,Nimodipine
,7779142,"Css,max","The Css,max of nimodipine was increased after the combined administration of nimodipine (30 mg t.i.d.) and indometacin (25 mg b.i.d.) as compared with those after nimodipine monotherapy: 24.2 +/- 14.7 micrograms/l vs. 19.7 +/- 10.3 micrograms/l.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),[μg] / [l],24.2,42868,DB00393,Nimodipine
,7779142,"Css,max","The Css,max of nimodipine was increased after the combined administration of nimodipine (30 mg t.i.d.) and indometacin (25 mg b.i.d.) as compared with those after nimodipine monotherapy: 24.2 +/- 14.7 micrograms/l vs. 19.7 +/- 10.3 micrograms/l.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),[μg] / [l],19.7,42869,DB00393,Nimodipine
,7779142,AUCss,Nimodipine AUCss slightly increased under indometacin co-medication from 57.9 +/- 27.5 micrograms.,Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),μg,57.9,42870,DB00393,Nimodipine
,7779142,relative bioavailability,"h.l-1, resulting in a mean relative bioavailability of nimodipine of 111% with a 90%-confidence interval of 96-128% for the combined medication.",Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7779142/),%,111,42871,DB00393,Nimodipine
,19810008,flow rate,"A 100 microL plasma sample was extracted by methyl tert-butyl ether after spiking the samples with nimodipine (internal standard) and performed on an XTerra(R)MS-C(18) column (150 mm x 2.1 mm, 3.5 mum) with the mobile phase of acetonitrile-water-formic acid (80:20:0.2, v/v) at a flow rate of 0.2 mL/min in a run time of 8.5 min.",Highly sensitive determination of Schisandrin and Schisandrin B in plasma of rats after administration of Wurenchun (Fructus Schisandrae Chinensis Extracts) preparations by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19810008/),[ml] / [min],0.2,46828,DB00393,Nimodipine
,19810008,run time,"A 100 microL plasma sample was extracted by methyl tert-butyl ether after spiking the samples with nimodipine (internal standard) and performed on an XTerra(R)MS-C(18) column (150 mm x 2.1 mm, 3.5 mum) with the mobile phase of acetonitrile-water-formic acid (80:20:0.2, v/v) at a flow rate of 0.2 mL/min in a run time of 8.5 min.",Highly sensitive determination of Schisandrin and Schisandrin B in plasma of rats after administration of Wurenchun (Fructus Schisandrae Chinensis Extracts) preparations by LC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19810008/),min,8.5,46829,DB00393,Nimodipine
,22241592,max,"Mean concentrations for nimodipine were 46.9 ng/ml (SD: 6.4; min. 4.1 and max. 92.7 ng/ml) in intraoperative serum, 73.2 ng/ml (SD: 16.7; min. 6.6 and max.",Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22241592/),[ng] / [ml],73.2,48086,DB00393,Nimodipine
,16681041,absolute bioavailability (A.B%),"The absolute bioavailability (A.B%) of nimodipine in the rabbits pretreated with morin was significantly (p < 0.05 at 10 mg/kg, p < 0.01 at 20 mg/kg) higher (54.1-65.0%) than the control (36.7%).","Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681041/),%,54.1-65.0,48741,DB00393,Nimodipine
,16681041,absolute bioavailability (A.B%),"The absolute bioavailability (A.B%) of nimodipine in the rabbits pretreated with morin was significantly (p < 0.05 at 10 mg/kg, p < 0.01 at 20 mg/kg) higher (54.1-65.0%) than the control (36.7%).","Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16681041/),%,36.7,48742,DB00393,Nimodipine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,16.7,53367,DB00393,Nimodipine
,1628595,blood,Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53368,DB00393,Nimodipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,22.4,53369,DB00393,Nimodipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,11.2,53370,DB00393,Nimodipine
,1628595,brain elimination half-lives (t1/2),Estimated blood and brain elimination half-lives (t1/2) of NMD (16.7 and 22.4 min) were slightly longer than those of NFD (11.2 and 14.7 min).,Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1628595/),min,14.7,53371,DB00393,Nimodipine
,26584914,relative bioavailability,"The pharmacokinetic results showed that the relative bioavailability was 397 % in comparison with Nimotop(®), suggesting that NCs are an efficient strategy for improving the oral bioavailability of poorly water-soluble drugs.",Formulation of nimodipine nanocrystals for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26584914/),%,397,60691,DB00393,Nimodipine
,3814462,Apparent oral clearance,"Apparent oral clearance of nimodipine in the cirrhotic group was significantly lower than that observed in the normal group (187 +/- 163 l h-1 vs 469.6 +/- 198.4 l h-1, P less than 0.01).",Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814462/),[l] / [h],187,65309,DB00393,Nimodipine
,3814462,Apparent oral clearance,"Apparent oral clearance of nimodipine in the cirrhotic group was significantly lower than that observed in the normal group (187 +/- 163 l h-1 vs 469.6 +/- 198.4 l h-1, P less than 0.01).",Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814462/),[l] / [h],469.6,65310,DB00393,Nimodipine
,18082350,flow rate,"The separation was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with water and acetonitrile (both containing 0.1% formic acid) as the mobile phase under gradient conditions at a flow rate of 0.35 ml/min.",Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082350/),[ml] / [min],0.35,66471,DB00393,Nimodipine
over,1400813,Absolute recovery,Absolute recovery of nimodipine from plasma was over 95% with a lower limit of quantitation of 10 ng/ml.,High-performance liquid chromatographic determination of the calcium channel blocker nimodipine in monkey plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1400813/),%,95,72223,DB00393,Nimodipine
,8249618,T1/2K,"The plasma concentration-time curve fitted to a first order absorption, 1-compartment open model, and the T1/2K was around 2 h.",Pharmacokinetics and relative bioavailability of nimodipine capsules and tablets in 8 Chinese healthy men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249618/),h,2,76913,DB00393,Nimodipine
,32806316,PDI,The optimized NM loaded LNC showed particle size of 35.94 ± 0.14 nm and PDI of 0.146 ± 0.045.,Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: In vitro optimization and in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32806316/),,0.146,79297,DB00393,Nimodipine
,32794077,absolute bioavailability,The absolute bioavailability after io administration was higher than that after ig administration (40.05% vs. 5.67%).,"Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32794077/),%,40.05,80252,DB00393,Nimodipine
,32794077,absolute bioavailability,The absolute bioavailability after io administration was higher than that after ig administration (40.05% vs. 5.67%).,"Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32794077/),%,5.67,80253,DB00393,Nimodipine
,32358897,absolute recoveries,"The mean absolute recoveries of the nine analytes were 85-106%, and all matrix effects were in the range 80-120%.",Development of a sensitive and rapid UHPLC-MS/MS method for simultaneous quantification of nine compounds in rat plasma and application in a comparative pharmacokinetic study after oral administration of Xuefu Zhuyu Decoction and nimodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32358897/),%,85-106,80411,DB00393,Nimodipine
,2737224,steady-state plasma concentration,The plasma concentrations increased with increasing dose; at the highest dose a mean steady-state plasma concentration of 22.1 ng.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),ng,22.1,81328,DB00393,Nimodipine
,2737224,plasma clearance,"ml-1 was obtained, and the mean plasma clearance was 1.41.kg-1.h-1.",Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),1/[h·kg],1.41,81329,DB00393,Nimodipine
,2737224,steady-state plasma concentration,A mean steady-state plasma concentration of 17.6 ng.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),ng,17.6,81330,DB00393,Nimodipine
,2737224,plasma clearance,ml-1 was obtained and the mean plasma clearance was 1.91.kg-1.h-1.,Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737224/),,1.91.,81331,DB00393,Nimodipine
,12426519,peak concentration (C(max)),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],319.6,82575,DB00393,Nimodipine
,12426519,area under the curve (AUC),"The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319.6 +/- 38.9 ng/mL at the first sampling time; area under the curve (AUC), 239 +/- 25 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,239,82576,DB00393,Nimodipine
,12426519,terminal half-life,"h/mL; and terminal half-life, 3.12 +/- 0.97 hours.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),h,3.12,82577,DB00393,Nimodipine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],46.1,82578,DB00393,Nimodipine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],81.7,82579,DB00393,Nimodipine
,12426519,C(max),"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[ng] / [ml],131.6,82580,DB00393,Nimodipine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],119,82581,DB00393,Nimodipine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),[h·ng] / [ml],256,82582,DB00393,Nimodipine
,12426519,AUC,"After oral administration, the drug kinetics was linear in the administered dose range and the pharmacokinetic parameters were as follows: C(max)(30 mg), 46.1 +/- 5.8 ng/mL; C(max)(60 mg), 81.7 +/- 14.6 ng/mL; C(max)(90 mg), 131.6 +/- 16.3 ng/mL; AUC(30 mg), 119 +/- 25 ng. h/mL; AUC(60 mg), 256 +/- 48 ng. h/mL; and AUC(90 mg), 389 +/- 54 ng.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),ng,389,82583,DB00393,Nimodipine
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,2,82584,DB00393,Nimodipine
,12426519,bioavailability,"The half-life was similar to the values observed after intravenous administration, whereas the bioavailability ranged between 2% and 5.9%.",Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426519/),%,5.9,82585,DB00393,Nimodipine
,28933097,entrapment efficiency,"According to the results, the entrapment efficiency and drug loading of NMD were (79.71±0.73)%, (1.74±0.02)%, those of TMP were (40.26±1.51)% and (4.38±0.16)%.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),%,79.71,85690,DB00393,Nimodipine
,28933097,entrapment efficiency,"According to the results, the entrapment efficiency and drug loading of NMD were (79.71±0.73)%, (1.74±0.02)%, those of TMP were (40.26±1.51)% and (4.38±0.16)%.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),%,40.26,85691,DB00393,Nimodipine
,28933097,drug loading,"According to the results, the entrapment efficiency and drug loading of NMD were (79.71±0.73)%, (1.74±0.02)%, those of TMP were (40.26±1.51)% and (4.38±0.16)%.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),%,1.74,85692,DB00393,Nimodipine
,28933097,drug loading,"According to the results, the entrapment efficiency and drug loading of NMD were (79.71±0.73)%, (1.74±0.02)%, those of TMP were (40.26±1.51)% and (4.38±0.16)%.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),%,40.26,85693,DB00393,Nimodipine
,28933097,drug loading,"According to the results, the entrapment efficiency and drug loading of NMD were (79.71±0.73)%, (1.74±0.02)%, those of TMP were (40.26±1.51)% and (4.38±0.16)%.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),%,4.38,85694,DB00393,Nimodipine
,28933097,t1/2β,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),h,1.097,85695,DB00393,Nimodipine
,28933097,t1/2β,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),h,1.055,85696,DB00393,Nimodipine
,28933097,t1/2β,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),h,1.950,85697,DB00393,Nimodipine
,28933097,t1/2β,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),h,1.860,85698,DB00393,Nimodipine
,28933097,t1/2β,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),h,2.497,85699,DB00393,Nimodipine
,28933097,CL,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),[h] / [l],0.778,85700,DB00393,Nimodipine
,28933097,CL,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),[h] / [l],1.133,85701,DB00393,Nimodipine
,28933097,CL,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),[h] / [l],0.247,85702,DB00393,Nimodipine
,28933097,CL,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),[h] / [l],0.497,85703,DB00393,Nimodipine
,28933097,CL,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),[h] / [l],0.297,85704,DB00393,Nimodipine
,28933097,AUC0-t,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),,514.218,85705,DB00393,Nimodipine
,28933097,AUC0-t,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),,352.916,85706,DB00393,Nimodipine
,28933097,AUC0-t,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),,1 618.429,85707,DB00393,Nimodipine
,28933097,AUC0-t,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),,804.110,85708,DB00393,Nimodipine
,28933097,AUC0-t,"On the basis of the major parameters for in vivo pharmacokinetic and brain distribution, t1/2β of NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension, NMD/TMP-NPs were (1.097±0.146), (1.055±0.06), (1.950±0.140), (1.860±0.096), (2.497±0.475） h, CL were (0.778±0.098), (1.133±0.111), (0.247±0.023), (0.497±0.040), (0.297±0.024) h•L-1, AUC0-t in rat plasma were (514.218±60.383), (352.916±33.691), (1 618.429±240.198), (804.110±75.804), (1 349.058±215.497) μg•h•L⁻¹, respectively, and AUC0-t in brain were 0.301 9, 0.624 8, 1.068 6, 1.313 0, 1.046 5 mg•h•L⁻¹, respectively.",[Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28933097/),,1 349,85709,DB00393,Nimodipine
,8861735,C(max),"Stereoselective disposition of nimodipine could be observed in all cases investigated, resulting in pronounced differences in AUC and C(max) values favoring the (R)-(+)-isomer in respect of higher oral bioavailability: After single doses of 60 mg nimodipine, for instance, (R)/(S)-ratios for AUC were ranging from 5.5 - 10.0 (g.mean/SD: 7.4/1.3) in young Caucasians, for C(max) from 4.4 - 7.7 (g.mean/SD: 5.9/1.3).",No interethnic differences in stereoselective disposition of oral nimodipine between Caucasian and Japanese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8861735/),,4.4 - 7.7,86783,DB00393,Nimodipine
,16882548,ratio of AUC,The ratio of AUC values of the nanoparticles to the solution was 1.56 in CSF.,The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16882548/),,1.56,90886,DB00393,Nimodipine
,27318642,flow rate,Then the analytes were successfully separated by running gradient elution with the mobile phase consisting of 0.1% formic acid in water and methanol at a flow rate of 0.6mL/min.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),[ml] / [min],0.6,91312,DB00393,Nimodipine
,27318642,extraction recoveries,The mean extraction recoveries of the analytes were within 69.82%-103.5% and the matrix were within 82.8%-110.0%.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),%,69,91313,DB00393,Nimodipine
,27318642,extraction recoveries,The mean extraction recoveries of the analytes were within 69.82%-103.5% and the matrix were within 82.8%-110.0%.,"Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba dispersible tablets and Nimodipine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27318642/),%,82,91314,DB00393,Nimodipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00393,Nimodipine
,17240061,"maximal concentration, C(max)","In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],2.7,101476,DB00393,Nimodipine
,17240061,C(max),"In pre-treated rats with V, hippocampal PHT concentrations were lower in MP (maximal concentration, C(max): 2.7+/-0.3 microg ml(-1), p<0.05 versus C rats) than in C animals (C(max): 5.3+/-0.9 microg ml(-1)).",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],5.3,101477,DB00393,Nimodipine
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],4.5,101478,DB00393,Nimodipine
,17240061,C(max),"Control rats pre-treated with NIMO showed similar results (C(max): 4.5+/-0.8 microg ml(-1)) than those pre-treated with V. NIMO pre-treatment of MP rats showed higher PHT concentrations (C(max): 6.8+/-1.0 microg ml(-1), p<0.05) when compared with V pre-treated MP group.",Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17240061/),[μg] / [ml],6.8,101479,DB00393,Nimodipine
,22001996,50% inhibition concentration (IC(50)),"Baicalein inhibited CYP3A4 enzyme activity in a concentration-dependent manner, with a 50% inhibition concentration (IC(50)) of 9.2 μM.",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),μM,9.2,102968,DB00393,Nimodipine
,22001996,absolute bioavailability,"Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0-35.3%, which was significantly enhanced (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg) compared to the oral control group (22.3%).",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),%,31.0-35.3,102969,DB00393,Nimodipine
,22001996,absolute bioavailability,"Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0-35.3%, which was significantly enhanced (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg) compared to the oral control group (22.3%).",Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22001996/),%,22.3,102970,DB00393,Nimodipine
>,15488232,concentrations,Mean nimodipine concentrations at 24 h were >7 ng/ml in both healthy animals (12.9 +/- 10.0 ng/ml) and in animals with SAH (11.8 +/- 4.6 ng/ml) that received 2.5 mg/kg of subcutaneous nimodipine.,Subcutaneous administration of nimodipine improves bioavailability in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15488232/),[ng] / [ml],7,108269,DB00393,Nimodipine
,15488232,concentrations,Mean nimodipine concentrations at 24 h were >7 ng/ml in both healthy animals (12.9 +/- 10.0 ng/ml) and in animals with SAH (11.8 +/- 4.6 ng/ml) that received 2.5 mg/kg of subcutaneous nimodipine.,Subcutaneous administration of nimodipine improves bioavailability in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15488232/),[ng] / [ml],12.9,108270,DB00393,Nimodipine
,15488232,concentrations,Mean nimodipine concentrations at 24 h were >7 ng/ml in both healthy animals (12.9 +/- 10.0 ng/ml) and in animals with SAH (11.8 +/- 4.6 ng/ml) that received 2.5 mg/kg of subcutaneous nimodipine.,Subcutaneous administration of nimodipine improves bioavailability in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15488232/),[ng] / [ml],11.8,108271,DB00393,Nimodipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.51,108535,DB00393,Nimodipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.70,108536,DB00393,Nimodipine
,16470916,maximal plasma concentration (C(max)),"The maximal plasma concentration (C(max)) of the three treated groups were 0.51, 0.70 and 0.81 microg/ml, respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[μg] / [ml],0.81,108537,DB00393,Nimodipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],1.81,108538,DB00393,Nimodipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],2.83,108539,DB00393,Nimodipine
,16470916,area under the concentration-time curve (AUC(0-8)),"The area under the concentration-time curve (AUC(0-8)) were 1.81, 2.83 and 3.63 microg/(h.ml(-1)), respectively.",[Effect of kaempferol on the pharmacokinetics of nifedipine in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16470916/),[h·μg] / [ml],3.63,108540,DB00393,Nimodipine
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,491.2,109953,DB00393,Nimodipine
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,122.1,109954,DB00393,Nimodipine
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,417.1,109955,DB00393,Nimodipine
,17903476,m/z,"Quantification was performed using multiple reaction monitoring (MRM) of the transitions m/z 491.2-->122.1 and m/z 417.1-->122.1 for cilnidipine and for the IS, respectively.","Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),,122.1,109956,DB00393,Nimodipine
,17903476,analysis time,The analysis time for each run was 3.0 min.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),min,3.0,109957,DB00393,Nimodipine
,17903476,recoveries,The recoveries were between 92.71% and 97.64%.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),%,92.71,109958,DB00393,Nimodipine
,17903476,recoveries,The recoveries were between 92.71% and 97.64%.,"Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17903476/),%,97.64,109959,DB00393,Nimodipine
,30243471,flow rate,An isocratic elution of samples was performed on capcell pak C8 DD S5 column (4.6mm×250mm particle size 5μm) column with mobile phase consisting 5mM Phosphate Buffer (pH 4.8 adjusted with dilute ortho-phosphoric acid solution): acetonitrile (25:75:v/v) delivered at flow rate 1.0mLmin-1.,Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[mlmin],1.0,110394,DB00393,Nimodipine
,30243471,LODs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.055,110395,DB00393,Nimodipine
,30243471,LOQs,"LODs and LOQs for felodipine were found to be 0.055 and 0.201μgmL-1, respectively.",Validated RP-HPLC method for quantification of felodipine in rabbit plasma: Application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30243471/),1/[μgml],0.201,110396,DB00393,Nimodipine
,7962672,clearance,Values for tirilazad mesylate clearance (34.9 +/- 8.96 L/hr) and half-life (29 +/- 7.83 hr) were consistent with previous studies.,Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7962672/),[l] / [h],34.9,112999,DB00393,Nimodipine
,7962672,half-life,Values for tirilazad mesylate clearance (34.9 +/- 8.96 L/hr) and half-life (29 +/- 7.83 hr) were consistent with previous studies.,Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7962672/),h,29,113000,DB00393,Nimodipine
,8156970,ED50,The calculated ED50 for NMD was 87 mg/kg.,Dose-response relationships with nimodipine against electroshock seizures in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156970/),[mg] / [kg],87,114266,DB00393,Nimodipine
,4010869,maximal plasma concentration,After an oral dose of 120 mg an average maximal plasma concentration 106 micrograms/l was recorded 45 to 60 minutes later.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),[μg] / [l],106,122122,DB00393,Nimodipine
,4010869,half lives,After i.v. administration a biphasic elimination with half lives of 7 min and 1 hour was observed.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),min,7,122123,DB00393,Nimodipine
,4010869,half lives,After i.v. administration a biphasic elimination with half lives of 7 min and 1 hour was observed.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),h,1,122124,DB00393,Nimodipine
,4010869,plasma concentrations,In patients with subarachnoid hemorrhage receiving a continuous infusion of 2 mg/hour the mean nimodipine plasma concentrations ranged between 36 and 72 micrograms/l.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),[μg] / [l],36 and 72,122125,DB00393,Nimodipine
,4010869,cerebrospinal fluid (CSF) levels,Mean cerebrospinal fluid (CSF) levels amounted to 0.3 +/- 0.2 microgram/l in patients whose mean plasma concentrations were 76.9 +/- 34.0 micrograms/l.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),[μg] / [l],0.3,122126,DB00393,Nimodipine
,4010869,plasma concentrations,Mean cerebrospinal fluid (CSF) levels amounted to 0.3 +/- 0.2 microgram/l in patients whose mean plasma concentrations were 76.9 +/- 34.0 micrograms/l.,Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010869/),[μg] / [l],76.9,122127,DB00393,Nimodipine
,27709016,AUC0-24 h,"As the results shown, for L-form of Nim (L-Nim), the AUC0-24 h in 2-month-old rats was 343.68±47.15 ng·h/mL, which is 23.36% higher than that in 9-month-old rats.",Effect of age on the pharmacokinetics of polymorphic nimodipine in rats after oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27709016/),[h·ng] / [ml],343.68,124958,DB00393,Nimodipine
,27709016,AUC0-24 h,"For H-form of Nim (H-Nim), the AUC0-24 h in 2-month-old rats was 140.91±19.47 ng·h/mL, which is 54.64% higher than that in 9-month-old rats.",Effect of age on the pharmacokinetics of polymorphic nimodipine in rats after oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27709016/),[h·ng] / [ml],140.91,124959,DB00393,Nimodipine
,27709016,AUC0-24 h ratio,The AUC0-24 h ratio between H-Nim and L-Nim was 2.44 in 2-month-old rats and 3.06 in 9-month-old rats.,Effect of age on the pharmacokinetics of polymorphic nimodipine in rats after oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27709016/),,2.44,124960,DB00393,Nimodipine
,27709016,AUC0-24 h ratio,The AUC0-24 h ratio between H-Nim and L-Nim was 2.44 in 2-month-old rats and 3.06 in 9-month-old rats.,Effect of age on the pharmacokinetics of polymorphic nimodipine in rats after oral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27709016/),,3.06,124961,DB00393,Nimodipine
,30993887,flow rate,"The chromatographic separation was achieved on an ACQUITY UPC2 ™ BEH 2-EP column, and a gradient elution program was applied at a flow rate of 1.5 mL/min.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ml] / [min],1.5,127221,DB00393,Nimodipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],279.28,127222,DB00393,Nimodipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],265.13,127223,DB00393,Nimodipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[min·ng] / [ml],25608.00,127224,DB00393,Nimodipine
,30993887,area under concentration-time curve (0-720 min),"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],265.13,127225,DB00393,Nimodipine
,30993887,area under concentration-time curve (0-720 min),"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[min·ng] / [ml],28553.67,127226,DB00393,Nimodipine
,30837043,Cmax,The pharmacokinetic parameters in io group were as follows:Cmax:0.52 mg/ml;tmax:5.0 min;and AUC0-t:21.10 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [ml],0.52,127240,DB00393,Nimodipine
,30837043,tmax,The pharmacokinetic parameters in io group were as follows:Cmax:0.52 mg/ml;tmax:5.0 min;and AUC0-t:21.10 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),min,5.0,127241,DB00393,Nimodipine
,30837043,AUC0-t,The pharmacokinetic parameters in io group were as follows:Cmax:0.52 mg/ml;tmax:5.0 min;and AUC0-t:21.10 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [min·ml],21.10,127242,DB00393,Nimodipine
,30837043,Cmax,The main pharmacokinetic parameters in iv group were as follows:Cmax:3.62 mg/ml;and AUC0-t:52.58 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [ml],3.62,127243,DB00393,Nimodipine
,30837043,AUC0-t,The main pharmacokinetic parameters in iv group were as follows:Cmax:3.62 mg/ml;and AUC0-t:52.58 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [min·ml],52.58,127244,DB00393,Nimodipine
,30837043,Cmax,The main pharmacokinetic parameters in ig group were as follows:Cmax:0.20 mg/ml;tmax:5.0 min;and AUC0-t:5.98 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [ml],0.20,127245,DB00393,Nimodipine
,30837043,tmax,The main pharmacokinetic parameters in ig group were as follows:Cmax:0.20 mg/ml;tmax:5.0 min;and AUC0-t:5.98 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),min,5.0,127246,DB00393,Nimodipine
,30837043,AUC0-t,The main pharmacokinetic parameters in ig group were as follows:Cmax:0.20 mg/ml;tmax:5.0 min;and AUC0-t:5.98 mg/(ml·min).,[Pharmacokinetics of Nimodipine after Intraocular Administration in Rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837043/),[mg] / [min·ml],5.98,127247,DB00393,Nimodipine
,19813460,flow rate,"The mobile phase was 10 mmol/L ammonium acetate solution-methanol (30:70, v/v) at the flow rate of 0.2 mL/min.",Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),[ml] / [min],0.2,128543,DB00393,Nimodipine
,19813460,relative bioavailability,The relative bioavailability was 103.7 +/- 12.3%.,Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19813460/),%,103.7,128544,DB00393,Nimodipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00393,Nimodipine
,3743617,mean plasma concentration,"During the i.v. infusion, the mean plasma concentration was 26.6 +/- 1.8 ng/ml.",Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743617/),[ng] / [ml],26.6,137383,DB00393,Nimodipine
,3743617,plasma clearance,The plasma clearance ranged from 0.57 to 1.771/kg/h and was negatively correlated with the age of the patient.,Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743617/),1/[h·kg],0.57 to 1.771,137384,DB00393,Nimodipine
,3743617,plasma concentration,"Immediately prior to successive oral doses, the mean plasma concentration was 13.2 ng/ml (range less than 3-38.8 ng/ml).",Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743617/),[ng] / [ml],13.2,137385,DB00393,Nimodipine
,3743617,peak level,The peak level was usually found after 1 h; it ranged from 7.0-96.0 ng/ml.,Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743617/),[ng] / [ml],7.0-96.0,137386,DB00393,Nimodipine
,3743617,bioavailability,Mean bioavailability was 15.9%.,Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743617/),%,15.9,137387,DB00393,Nimodipine
,28156162,oral bioavailability,"NM has poor oral bioavailability (5-13%) due to its low aqueous solubility, and extensive first pass metabolism.",Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156162/),%,5-13,139520,DB00393,Nimodipine
,28156162,drug-targeting efficiency,The drug-targeting efficiency of NM to the brain after intranasal administration was calculated to be 1872.82%.,Contribution of both olfactory and systemic pathways for brain targeting of nimodipine-loaded lipo-pluronics micelles: in vitro characterization and in vivo biodistribution study after intranasal and intravenous delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156162/),%,1872.82,139521,DB00393,Nimodipine
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,3.9,140864,DB00393,Nimodipine
,1777370,half-lives,"3. Nimodipine half-lives were shorter in enzyme-induced patients than in controls (3.9 +/- 2.0 h vs 9.1 +/- 3.4 h, means +/- s.d., P less than 0.01), but this difference could be artifactual since in the patients drug concentrations declined rapidly below the limit of assay, thus preventing identification of a possible slower terminal phase.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,9.1,140865,DB00393,Nimodipine
,1777370,half-lives,"In valproate-treated patients, half-lives (8.2 +/- 1.8 h) were similar to those found in controls.",Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777370/),h,8.2,140866,DB00393,Nimodipine
,4096729,terminal half-lives,Dependent on the observation period (24-216 h) terminal half-lives for the elimination of radioactivity from plasma ranging between 4.6 h (female rat) and 157 h (dog) were observed.,"Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096729/),h,4.6,142334,DB00393,Nimodipine
,4096729,terminal half-lives,Dependent on the observation period (24-216 h) terminal half-lives for the elimination of radioactivity from plasma ranging between 4.6 h (female rat) and 157 h (dog) were observed.,"Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096729/),h,157,142335,DB00393,Nimodipine
,4096729,Binding,Binding of [14C]nimodipine to plasma proteins of rat and dog was about 97%.,"Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4096729/),%,97,142336,DB00393,Nimodipine
,26241752,oral bioavailability,"However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h).","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,5-13,144692,DB00393,Nimodipine
,26241752,elimination half-life,"However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h).","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),h,1-2,144693,DB00393,Nimodipine
,26241752,zeta potential,"The selected NM-loaded PPPMM, containing PC to Pluronics(®) molar ratio of 75:25, showed a drug payload, SE, micellar size and zeta potential of 1.06 ± 0.03 mg/mL, 99.2 ± 2.01%, 571.5 ± 11.87 nm and -31.2 ± 0.06 mv, respectively.","Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),mv,-31.2,144694,DB00393,Nimodipine
,26241752,bioavailability,The in vivo pharmacokinetic study showed greater bioavailability of NM in plasma (232%) and brain (208%) of rats from NM-loaded PPPMM compared to that of the drug solution due to the efficiency of flexible NTMM to enhance absorption of NM from the intestinal mucosa.,"Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,232,144695,DB00393,Nimodipine
,26241752,bioavailability,The in vivo pharmacokinetic study showed greater bioavailability of NM in plasma (232%) and brain (208%) of rats from NM-loaded PPPMM compared to that of the drug solution due to the efficiency of flexible NTMM to enhance absorption of NM from the intestinal mucosa.,"Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26241752/),%,208,144696,DB00393,Nimodipine
,9121810,half-life,"In order to take into account both the short duration of treatment (8 days), and nimodipine's pharmacokinetic characteristics (half-life of 6 h and steady state of 36 h), we compared treatment with nimodipine or placebo on the third day of use, at which time, likewise, there were no statistically significant differences on any of the scales.",Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9121810/),h,6,146211,DB00393,Nimodipine
,9121810,steady state,"In order to take into account both the short duration of treatment (8 days), and nimodipine's pharmacokinetic characteristics (half-life of 6 h and steady state of 36 h), we compared treatment with nimodipine or placebo on the third day of use, at which time, likewise, there were no statistically significant differences on any of the scales.",Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9121810/),h,36,146212,DB00393,Nimodipine
,18499371,AUC(0-infinity),"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[nghml],2488,146263,DB00393,Nimodipine
,18499371,Cmax,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[ngml],321,146264,DB00393,Nimodipine
,18499371,AUC0-infinity,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[nghml],2272,146265,DB00393,Nimodipine
,18499371,Cmax,"The results suggested that there was no significant difference in the areas under the plasma concentration-time curve and the mean peak concentration between NMD-SSC (AUC(0-infinity)=2488+/-433nghmL(-1), Cmax=321+/-78ngml(-1)) and Nimotop (AUC0-infinity=2272+/-398nghmL(-1), Cmax=293+/-73ngmL(-1)) (P>0.05).",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),1/[ngml],293,146266,DB00393,Nimodipine
,18499371,tmax,"However, the apparent rate of absorption of NMD from NMD-SSC (tmax=1.3h) was markedly faster than that from Nimotop (tmax=3.1h) (P<0.05), which indicates that as a fast release preparation, NMD-SSC is well absorbed.",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),h,1.3,146267,DB00393,Nimodipine
,18499371,tmax,"However, the apparent rate of absorption of NMD from NMD-SSC (tmax=1.3h) was markedly faster than that from Nimotop (tmax=3.1h) (P<0.05), which indicates that as a fast release preparation, NMD-SSC is well absorbed.",Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18499371/),h,3.1,146268,DB00393,Nimodipine
,23611843,runtime,"Following extraction by methyl tert-butyl ether, the analytes were separated on a Thermo Syncronis C18 column by a gradient elution within a runtime of 9min.","Simultaneous determination of limonin, dictamnine, obacunone and fraxinellone in rat plasma by a validated UHPLC-MS/MS and its application to a pharmacokinetic study after oral administration of Cortex Dictamni extract. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23611843/),min,9,150165,DB00393,Nimodipine
,12016918,recoveries,The plasma samples were extracted using a mixture of ethyl ether and n-hexane (2:1) to give mean recoveries of 97.3% of felodipine.,[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),%,97.3,155139,DB00393,Nimodipine
,12016918,detection limits,The detection limits for felodipine was 0.25 ng.,[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),ng,0.25,155140,DB00393,Nimodipine
,12016918,T1/2 alpha,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,0.76,155141,DB00393,Nimodipine
,12016918,T1/2 beta,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,16.09,155142,DB00393,Nimodipine
,12016918,Cmax,"Its main pharmacokinetic parameters were: T1/2 alpha = 0.76 h, T1/2 beta = 16.09 h, Cmax = 4.78 ng.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),ng,4.78,155143,DB00393,Nimodipine
,12016918,Tmax,"ml-1, Tmax = 2.01 h, AUC = 45.2 h.ng.ml-1.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),h,2.01,155144,DB00393,Nimodipine
,12016918,AUC,"ml-1, Tmax = 2.01 h, AUC = 45.2 h.ng.ml-1.",[Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016918/),[h·ng] / [ml],45.2,155145,DB00393,Nimodipine
,23112426,50% inhibition concentration (IC(50)),Pravastatin inhibited CYP3A4 enzyme activity in a concentration-dependent manner with a 50% inhibition concentration (IC(50)) of 14 µM.,Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112426/),μM,14,158380,DB00393,Nimodipine
,23112426,absolute bioavailability (AB),"Consequently, the absolute bioavailability (AB) of nimodipine with pravastatin (1 mg/kg) was 31.1%, which was significantly enhanced compared with the oral control group.",Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112426/),%,31.1,158381,DB00393,Nimodipine
,7841566,maximum tolerated dose,The maximum tolerated dose of nimodipine was found to be 1 mg/h.,Safety and tolerance of intravenous nimodipine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7841566/),[mg] / [h],1,159765,DB00393,Nimodipine
,17069421,run time,A run time of 3 min for each sample made it possible to analyze more than 250 human plasma samples per day.,Liquid chromatographic-electrospray tandem mass spectrometric method for the quantification of nimodipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17069421/),min,3,162385,DB00393,Nimodipine
,25652785,CSF/Plasma concentration ratio,CSF/Plasma concentration ratio of nimodipine after oral administration of 60 mg at 1 h was 0.013 ± 0.0005.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),,0.013,170942,DB00393,Nimodipine
,25652785,terminal elimination half-life,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),h,1.8,170943,DB00393,Nimodipine
,25652785,plasma clearance,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),[l] / [h·kg],40.3,170944,DB00393,Nimodipine
,25652785,plasma clearance,The mean terminal elimination half-life of nimodipine after i.v. bolus dose 0.72 mg was 1.8 h and mean plasma clearance was 40.3 and 3.4 l/h/kg.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),[l] / [h·kg],3.4,170945,DB00393,Nimodipine
,25652785,Absolute bioavailability,Absolute bioavailability was 22 %.,"Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25652785/),%,22,170946,DB00393,Nimodipine
,17318527,AUC(0-4),"Nimodipine AUC values (expressed in mug min/ml) were lower in the eight SAH patients receiving enteral nimodipine [AUC(0-4) range: 0.13-5.4 (median: 0.32); AUC(24-28) range: 0.16-6.1 (0.71); AUC(72-76) range: 0.47-20.6 (1.9)] than in the nine patients receiving a continuous intravenous infusion of nimodipine [AUC(0-4) range: 2.4-4.9 (3.4), p=0.059; AUC(24-28) range: 4.7-10.3 (7.3), p=0.001; AUC(72-76) range: 3.4-8.6 (6.9), p=0.001].",Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318527/),[min·μg] / [ml],0.32,172619,DB00393,Nimodipine
,17318527,AUC(72-76),"Nimodipine AUC values (expressed in mug min/ml) were lower in the eight SAH patients receiving enteral nimodipine [AUC(0-4) range: 0.13-5.4 (median: 0.32); AUC(24-28) range: 0.16-6.1 (0.71); AUC(72-76) range: 0.47-20.6 (1.9)] than in the nine patients receiving a continuous intravenous infusion of nimodipine [AUC(0-4) range: 2.4-4.9 (3.4), p=0.059; AUC(24-28) range: 4.7-10.3 (7.3), p=0.001; AUC(72-76) range: 3.4-8.6 (6.9), p=0.001].",Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318527/),,3.4-8.6,172620,DB00393,Nimodipine
,24333769,flow rate,"The mobile phase was carbon dioxide (≥99.99%) and methanol (92:8, v/v) at a flow rate of 2ml/min, the compensation solvent was methanol with 2% formic acid at a flow rate of 0.2ml/min and a total analysis time of 1.5min for each sample.",Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333769/),[ml] / [min],0.2,175122,DB00393,Nimodipine
,24333769,total analysis time,"The mobile phase was carbon dioxide (≥99.99%) and methanol (92:8, v/v) at a flow rate of 2ml/min, the compensation solvent was methanol with 2% formic acid at a flow rate of 0.2ml/min and a total analysis time of 1.5min for each sample.",Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333769/),min,1.5,175123,DB00393,Nimodipine
,24333769,m/,"The multiple reaction-monitoring mode was used for quantification of ion transitions at m/z 473.32→354.10 and 419.00→343.10 for lacidipine and internal standard, respectively.",Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333769/),,473.32,175124,DB00393,Nimodipine
,24333769,m/,"The multiple reaction-monitoring mode was used for quantification of ion transitions at m/z 473.32→354.10 and 419.00→343.10 for lacidipine and internal standard, respectively.",Development of a supercritical fluid chromatography-tandem mass spectrometry method for the determination of lacidipine in beagle dog plasma and its application to a bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333769/),,419.00,175125,DB00393,Nimodipine
,7757308,peak nimodipine plasma concentration,Mean peak nimodipine plasma concentration was decreased after combined administration of the two drugs (16.1 +/- 8.1 micrograms/l vs. 12.4 +/- 9.5 micrograms/l).,Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[μg] / [l],16.1,177821,DB00393,Nimodipine
,7757308,peak nimodipine plasma concentration,Mean peak nimodipine plasma concentration was decreased after combined administration of the two drugs (16.1 +/- 8.1 micrograms/l vs. 12.4 +/- 9.5 micrograms/l).,Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[μg] / [l],12.4,177822,DB00393,Nimodipine
,7757308,AUCss,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[l·μg] / [l],44.9,177823,DB00393,Nimodipine
,7757308,AUCss,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[h·μg] / [l],38.8,177824,DB00393,Nimodipine
,7757308,AUC ratio,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),%,88.8,177825,DB00393,Nimodipine
,7757308,relative bioavailability,"The relative bioavailability of propranolol was 104.1 +/- 38.3% after the combined propranolol and nimodipine medication, all other pharmacokinetic parameters remained unchanged.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),%,104.1,177826,DB00393,Nimodipine
,23668980,bioavailability,"The nanocrystals exhibited lower dissolution patterns than Nimotop(®) under non-sink condition, but bioavailability of the two nanocrystals (159.0 and 833.3 nm) was equivalent, about 2.6-fold higher than Nimotop(®).","Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668980/),nm,159.0,191446,DB00393,Nimodipine
,23668980,bioavailability,"The nanocrystals exhibited lower dissolution patterns than Nimotop(®) under non-sink condition, but bioavailability of the two nanocrystals (159.0 and 833.3 nm) was equivalent, about 2.6-fold higher than Nimotop(®).","Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668980/),nm,833.3,191447,DB00393,Nimodipine
,8299671,Css,"The values for Css, CL and CL.kg-1 were 33.5 micrograms.",Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299671/),μg,33.5,191734,DB00393,Nimodipine
,8299671,bioavailability,"l-1, 58 l.h-1 and 1.0 l.h-1 x kg-1 respectively; in survivors receiving the drug orally, bioavailability of the 30 mg tablet was 9%.",Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8299671/),%,9,191735,DB00393,Nimodipine
,29604372,oral bioavailability,"Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68 µg/mg, significantly improve the oral bioavailability of nimodipine; about 7-times higher than for the control drug solution (62% vs 9%).",Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604372/),%,62,197517,DB00393,Nimodipine
,29604372,oral bioavailability,"Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68 µg/mg, significantly improve the oral bioavailability of nimodipine; about 7-times higher than for the control drug solution (62% vs 9%).",Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29604372/),%,9,197518,DB00393,Nimodipine
,8328270,Tp,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),h,0.977,197926,DB00393,Nimodipine
,8328270,Cmax,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),[ng] / [ml],44.28,197927,DB00393,Nimodipine
,8328270,ka,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),1/[h],2.02,197928,DB00393,Nimodipine
,8328270,t1/2,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),h,1.63,197929,DB00393,Nimodipine
,8328270,Vd,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),[l] / [kg],26.25,197930,DB00393,Nimodipine
,8328270,AUC,"After administration of 120 mg dose of B, the pharmacokinetic parameters were as follows: Tp = 0.977 h, Cmax = 44.28 ng/ml, ka = 2.02 h-1, t1/2 = 1.63 h, Vd = 26.25 L/kg, AUC = 136.56 ng.h-1.ml-1.",[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),[ng] / [h·ml],136.56,197931,DB00393,Nimodipine
,8328270,bioavailability,The bioavailability of A and B relative to C was 16.01% and 82.39% respectively.,[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),%,16.01,197932,DB00393,Nimodipine
,8328270,bioavailability,The bioavailability of A and B relative to C was 16.01% and 82.39% respectively.,[Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8328270/),%,82.39,197933,DB00393,Nimodipine
,14628452,Tmax,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),h,2.1,202488,DB00393,Nimodipine
,14628452,CLs,"The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2.1 +/- 0.3) h, (197 +/- 5) microgram.L-1, (656 +/- 18) mL.min-1, (0.30 +/- 0.03) microgram.h.L-1, and R-(+)-nimodipine (1.7 +/- 0.5) h, (128 +/- 4) microgram.L-1, (381 +/- 4) mL.min-1, (0.53 +/- 0.03) microgram.",Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628452/),[h·μg] / [l],0.30,202489,DB00393,Nimodipine
,9861491,recovery,The recovery of nicardipine was 92.8-100.8% for plasma.,A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),%,92.8-100.8,210367,DB00393,Nimodipine
,9861491,Tmax,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),h,1.6,210368,DB00393,Nimodipine
,9861491,Cmax,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),[ng] / [ml],109.8,210369,DB00393,Nimodipine
,9861491,T1/2,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),h,5.35,210370,DB00393,Nimodipine
,9861491,AUC0-->infinity,"The results showed that the disposition of nicardipine was conformed to a two-compartment open model with Tmax = 1.6 +/- 0.3 h, Cmax = 109.8 +/- 38.7 ng/mL, T1/2 = 5.35 +/- 2.28 h and AUC0-->infinity = 322.1 +/- 69.6 ng/h/mI.",A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9861491/),[ng] / [h·mi],322.1,210371,DB00393,Nimodipine
,19429015,"maximal concentration, C(max)","In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],6.0,210613,DB00393,Nimodipine
,19429015,C(max),"In vehicle pre-treated rats, hippocampal phenobarbital concentrations were lower in MP (maximal concentration, C(max): 6.0+/-0.6 microg ml(-1), p<0.05) than in C animals (C(max): 9.4+/-0.9 microg ml(-1)).",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],9.4,210614,DB00393,Nimodipine
,19429015,C(max),Control rats pre-treated with nimodipine showed similar results (C(max): 10.7+/-0.6 microg ml(-1)) than those pre-treated with vehicle.,Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.7,210615,DB00393,Nimodipine
,19429015,C(max),"Nimodipine pre-treatment in MP rats enhanced hippocampal phenobarbital concentrations (C(max): 10.2+/-1.0 microg ml(-1), p<0.05) as compared with vehicle pre-treatment.",Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19429015/),[μg] / [ml],10.2,210616,DB00393,Nimodipine
,15693192,limit of detection,The limit of detection is 0.2 ng/mL.,High-performance liquid chromatography-electrospray ionization mass spectrometric determination of nisoldipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15693192/),[ng] / [ml],0.2,214319,DB00393,Nimodipine
,19408692,relative bioavailability,"Compared to nobiletin suspension, nobiletin liposomes possessed higher absorptive rate and longer MRT, and the relative bioavailability was 264.3% in rats.",[Preparation of self-assemble nobiletin proliposomes and its pharmacokinetics in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19408692/),%,264.3,218488,DB00393,Nimodipine
,12370099,clearance rate [CL(S)],Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[ml] / [kg·s],20.8,220882,DB00393,Nimodipine
,12370099,clearance rate [CL(S)],Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[ml] / [kg·s],31,220883,DB00393,Nimodipine
,12370099,AUC,Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[mg] / [s],2.08,220884,DB00393,Nimodipine
,12370099,AUC,Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s.,Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12370099/),[mg] / [s],1.6,220885,DB00393,Nimodipine
,6519852,peak plasma levels,In these subjects peak plasma levels of nimodipine ranged between 15.5 and 106.7 micrograms/1 on first treatment day and did not differ significantly from those on the 7th day of therapy ranging between 17.0 and 80 micrograms/1.,Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),μg,15.5 and 106.7,227197,DB00393,Nimodipine
,6519852,peak plasma levels,In these subjects peak plasma levels of nimodipine ranged between 15.5 and 106.7 micrograms/1 on first treatment day and did not differ significantly from those on the 7th day of therapy ranging between 17.0 and 80 micrograms/1.,Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),μg,17.0 and 80,227198,DB00393,Nimodipine
,6519852,terminal elimination half-life,"Mean terminal elimination half-life of nimodipine was 2.77 +/- 0.46 h in normal renal function, but was 22.23 +/- 6.94 h in patients with impaired renal function (12 patients with GFR less than 60 ml/min).",Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),h,2.77,227199,DB00393,Nimodipine
,6519852,terminal elimination half-life,"Mean terminal elimination half-life of nimodipine was 2.77 +/- 0.46 h in normal renal function, but was 22.23 +/- 6.94 h in patients with impaired renal function (12 patients with GFR less than 60 ml/min).",Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),h,22.23,227200,DB00393,Nimodipine
,6519852,area under the plasma level time curve (AUC),The mean area under the plasma level time curve (AUC) with 541.5 +/- 16.93 ng ml-1 h increased in patients with renal insufficiency compared to those with normal renal function (74.65 +/- 9.44 ng ml-1 h).,Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),[h·ng] / [ml],541.5,227201,DB00393,Nimodipine
,6519852,area under the plasma level time curve (AUC),The mean area under the plasma level time curve (AUC) with 541.5 +/- 16.93 ng ml-1 h increased in patients with renal insufficiency compared to those with normal renal function (74.65 +/- 9.44 ng ml-1 h).,Clinical pharmacokinetics of nimodipine in normal and impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519852/),[h·ng] / [ml],74.65,227202,DB00393,Nimodipine
,16877419,C(max),Values of C(max) displayed a large interindividual variance and ranged from 0 ng/mL to 57.5 ng/mL.,Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],0,240985,DB00393,Nimodipine
,16877419,C(max),Values of C(max) displayed a large interindividual variance and ranged from 0 ng/mL to 57.5 ng/mL.,Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],57.5,240986,DB00393,Nimodipine
,16877419,maximum nimodipine plasma concentrations (C(max)),"On average, maximum nimodipine plasma concentrations (C(max)) were 16.6 +/- 14.9 ng/mL and 12.0 +/- 10.3 ng/mL at day 1 and day 5, respectively (P = 0.068).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],16.6,240987,DB00393,Nimodipine
,16877419,maximum nimodipine plasma concentrations (C(max)),"On average, maximum nimodipine plasma concentrations (C(max)) were 16.6 +/- 14.9 ng/mL and 12.0 +/- 10.3 ng/mL at day 1 and day 5, respectively (P = 0.068).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),[ng] / [ml],12.0,240988,DB00393,Nimodipine
,16877419,t(max),"They were observed at 81 +/- 50 and at 93 +/- 40 minutes (t(max)) after the administration of nimodipine at day 1 and day 5, respectively (P = 0.43).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),min,81,240989,DB00393,Nimodipine
,16877419,t(max),"They were observed at 81 +/- 50 and at 93 +/- 40 minutes (t(max)) after the administration of nimodipine at day 1 and day 5, respectively (P = 0.43).",Nimodipine plasma concentration and retinal blood flow in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16877419/),min,93,240990,DB00393,Nimodipine
,23319300,entrapment efficiency (EE%),"The average diameter was 378.6±26.5 nm in distilled water with entrapment efficiency (EE%) of 84.7±5.9%, while the average diameter was 316.9±34.6 nm in 0.1 M hydrochloric acid solution with EE% of 72.8±4.7%.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),%,84,245517,DB00393,Nimodipine
,23319300,EE%,"The average diameter was 378.6±26.5 nm in distilled water with entrapment efficiency (EE%) of 84.7±5.9%, while the average diameter was 316.9±34.6 nm in 0.1 M hydrochloric acid solution with EE% of 72.8±4.7%.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),%,72.8,245518,DB00393,Nimodipine
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,0.75,245519,DB00393,Nimodipine
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,2,245520,DB00393,Nimodipine
,23319300,time of peak concentration,"In vivo experiments, areas under the plasma level-time curve of NPSC and nimodipine-hydrated liposomes increased 2.41 and 2.34 times more than that of nimodipine soft capsules, peak concentration increased 2.87 and 2.92 times, time of peak concentration from 0.75 to 2 and 1 h, respectively.","Liquid proliposomes of nimodipine drug delivery system: preparation, characterization, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23319300/),h,1,245521,DB00393,Nimodipine
,26350588,steady-state cerebral arterial concentrations,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ng] / [ml],200,246872,DB00393,Nimodipine
,26350588,steady-state cerebral arterial concentrations,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ng] / [ml],100,246873,DB00393,Nimodipine
,26350588,blood flow,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[ml] / [min],200,246874,DB00393,Nimodipine
,26350588,clearance,"According to our simulations, continuous IA nimodipine infusion at 2 mg/h and 1 mg/h resulted in steady-state cerebral arterial concentrations of about 200 ng/ml and 100 ng/ml assuming an ICA blood flow of 200 ml/min and a clearance of 70 l/h.",Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26350588/),[l] / [h],70,246875,DB00393,Nimodipine
,17132204,entrapment efficacy,"The particle size distribution, zeta potential, entrapment efficacy and assay of the NM-loaded LMs were found to be 188.2+/-5.4 nm, -31.6 mV, 94.2% and 1.04 mg mL(-1), respectively.",Formulation and evaluation of nimodipine-loaded lipid microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132204/),[mg] / [ml],1.04,249776,DB00393,Nimodipine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,75.0,254714,DB00393,Nimodipine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,79.0,254715,DB00393,Nimodipine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,44.2,254716,DB00393,Nimodipine
,22609590,logP,Nimodipine (NMD) is highly lipophilic antihypertensive drug having (logP 3.41) and 13% oral bioavailability.,Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609590/),,3.41,262126,DB00393,Nimodipine
,22609590,oral bioavailability,Nimodipine (NMD) is highly lipophilic antihypertensive drug having (logP 3.41) and 13% oral bioavailability.,Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609590/),%,13,262127,DB00393,Nimodipine
,22609590,zeta potential,"Optimised SLNs (F8) had particle size of 116±21 nm, zeta potential of -10±(-4.8) mV, EE of 93.66±9.72% and cumulative drug release of 87.52±2.54% in 10 h.",Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609590/),mv,-10,262128,DB00393,Nimodipine
,22609590,EE,"Optimised SLNs (F8) had particle size of 116±21 nm, zeta potential of -10±(-4.8) mV, EE of 93.66±9.72% and cumulative drug release of 87.52±2.54% in 10 h.",Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609590/),%,93.66,262129,DB00393,Nimodipine
,22609590,cumulative drug release,"Optimised SLNs (F8) had particle size of 116±21 nm, zeta potential of -10±(-4.8) mV, EE of 93.66±9.72% and cumulative drug release of 87.52±2.54% in 10 h.",Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22609590/),%,87.52,262130,DB00393,Nimodipine
,7772426,clearance,"Similarly, mean clearance of nimodipine was lower than predicted, that is 0.53 (range 0.40-0.72) litre kg-1 h-1.",Continuous infusion of nimodipine during coronary artery surgery: haemodynamic and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7772426/),[l] / [h·kg],0.53,263921,DB00393,Nimodipine
